Reverse, Double Down, or Skip? Salt Restriction, Fosfomycin & Monitors After Syncope
transcript
show notes
With Special Guest Dr. Austin White
Dr. Austin White returns to Inpatient Update to rethink three everyday decisions:
- ESBL UTIs: Could oral fosfomycin get your patient home without a PICC?
- Unexplained syncope: Should more patients leave with a cardiac monitor?
- Heart failure: Does that automatic low-sodium diet order actually help?
Plus, we break out the UNO cards to decide which findings change our practice, which make us double down, and which leave us waiting for more evidence.
Articles
Clinical Infectious Diseases, 2026
Randomized trial of 299 adults improving after 3–7 days of IV antibiotics for complicated ESBL UTIs.
- Oral fosfomycin 3 g daily vs continued IV therapy; 10 total treatment days.
- Clinical cure: 92.8% vs 95.2%; met noninferiority.
- Tested oral step-down after initial IV treatment.
Takeaway
Check oral options before ordering a PICC. Susceptible TMP-SMX or fluoroquinolones remain preferred. Consider fosfomycin for selected, improving patients with ESBL E. coli UTIs when those agents aren’t options. IDSA advises against oral fosfomycin step-down for ESBL bloodstream infections.
Related guidance: IDSA AMR Guidance, 2026 · IDSA Complicated UTI Guideline, 2025
Immediate Ambulatory Electrocardiographic Monitoring in Syncope
New England Journal of Medicine, 2026 — ASPIRED
Randomized trial of 2,234 adults with unexplained syncope after ED evaluation: immediate 14-day ECG monitoring vs usual care.
- Primary outcome: No significant reduction in syncope episodes at one year.
- Clinically significant arrhythmias detected: 22% vs 9%.
- Mortality: 1.5% vs 2.9% — an exploratory secondary finding that needs confirmation. Secondary analyses were not adjusted for multiple comparisons.
Takeaway
For selected patients with unexplained syncope and concern for arrhythmia, arrange monitoring before discharge and establish who will review the results.
Related guidance: 2017 ACC/AHA/HRS Syncope Guideline
Things We Do For No Reason™: Low Salt Diets for Patients With Acute Heart Failure
Journal of Hospital Medicine, 2026
A review of routine sodium restriction in acute heart failure.
- Small inpatient trials have not shown better decongestion or clinical outcomes.
- Aggressive sodium/fluid restrictions caused more thirst and sometimes lower caloric intake.
- Outpatient sodium reduction may improve symptoms or quality of life, but randomized evidence has not demonstrated fewer hospitalizations or deaths.
Takeaway
Reconsider the automatic 2-g sodium restriction. Prioritize diuresis, nutrition, and a plan that fits how the patient eats at home.
Related guidance:
- 2022 AHA/ACC/HFSA Heart Failure Guideline — avoid excessive sodium for congestive symptoms; no universal HF sodium target.
- 2024 HFA/ESC Consensus on Dietary Sodium and Fluid Intake — source of the 1.5–4 g/day sodium range discussed.
Practice-Changing Takeaways
- ESBL UTIs: Review oral options before committing to outpatient IV antibiotics.
- Unexplained syncope: When monitoring is indicated, get it started before the patient leaves.
- Heart failure: Reassess the default sodium restriction and prioritize decongestion and nutrition.
Want the cited articles and key takeaways by email? Join the Inpatient Update email list.
If this episode was useful, share it with one colleague who takes care of hospitalized patients.
Want the cited articles and key takeaways? Join the email list:
https://subscribe.inpatientupdate.com/
- Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by ESBL-Producing Enterobacteralespubmed.ncbi.nlm.nih.gov
- IDSA AMR Guidance, 2026idsociety.org
- IDSA Complicated UTI Guideline, 2025idsociety.org
- Immediate Ambulatory Electrocardiographic Monitoring in Syncopepubmed.ncbi.nlm.nih.gov